Xtandi and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Xtandi (enzalutamide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Norco, and have Prostate cancer.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Xtandi. It is created by eHealthMe based on reports of 51,433 people who have side effects when taking Xtandi from the FDA, and is updated regularly.

What is Xtandi?

Xtandi has active ingredients of enzalutamide. eHealthMe is studying from 51,498 Xtandi users. Check the latest studies of Xtandi.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 536 drugs and 467 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Jun, 22, 2026

51,433 people reported to have side effects when taking Xtandi.
Among them, 7 people (0.01%) have Second primary malignancy.

Could Xtandi cause Second primary malignancy?

Among these 7 people:

How long have people been on Xtandi when they have Second primary malignancy? *

What is the gender of people who have Second primary malignancy when taking Xtandi? *

female: 0.0 %
male: 100 %

What is the age of people who have Second primary malignancy when taking Xtandi? *

What are other drugs people take besides Xtandi? *

What are other side effects people have besides Second primary malignancy? *

Neuropathy Peripheral (surface nerve damage): 4 people, 57.14%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 57.14%
Disease Recurrence: 4 people, 57.14%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 57.14%
Bladder Neoplasm (bladder tumour): 4 people, 57.14%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 42.86%
Blood Count Abnormal: 2 people, 28.57%
Myeloid Leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 14.29%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 14.29%

What are the existing conditions these people have? *

Prostate Cancer: 5 people, 71.43%
Prostate Cancer Metastatic: 2 people, 28.57%

* Approximation only. Some reports may have incomplete information.

Do you take Xtandi and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xtandi:

Xtandi (51,498 reports)

Browse all side effects of Xtandi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (536 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (467 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enzalutamide (the active ingredients of Xtandi) and Xtandi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.